The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: (link sends e-mail)

Study Name on (link is external)
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
Study DrugQBW251
Type of Study DrugCFTR Modulation
Study TitleA randomized, double blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy subjects and multiple doses in cystic fibrosis patients
Study Phase2
Study SponsorNovartis

Link on (link is external) (link is external)

Participating ECFS-CTN sitesFrance: Lyon, Montpellier, West-Paris(Cochin)
Germany : Berlin, Cologne
Italy: Florence, Genoa, Milan, Rome, Verona
The Netherlands: Utrecht
UK: Belfast, London
Age18 Years to 55 Years